Hourly blood pressure monitoring after intravenous tissue plasminogen activator for ischemic stroke: does everyone need it?
OBJECTIVE
Blood pressure (BP) control is considered essential in patients treated with tissue plasminogen activator (tPA) for ischemic stroke, and it is recommended that BP be monitored every 15 minutes to 1 hour for 24 hours in these patients. We postulated that patients whose BP is not initially elevated are unlikely to have elevated BP later and, therefore, may not need prolonged BP monitoring.


METHODS
We performed a retrospective chart review of patients treated with intravenous tPA for ischemic stroke over a 3-year period. Patients with incomplete records were excluded.


RESULTS
Seventy-nine patients (35 male, age 68.8+/-14.3 years) were studied. Before tPA treatment, 16 patients (20%) had hypertension (systolic BP > or =185 or diastolic BP > or =110 mm Hg). All 16 patients had subsequent hypertension over the next 24 hours. Of the remaining 63, 27 patients (43%) had hypertension (systolic BP > or =180 or diastolic BP > or =105 mm Hg) within the first 6 hours. An additional 4 had minor transient systolic elevations (< or =182 mm Hg) after 6 hours that normalized without treatment. Neurological worsening, seen in 13 patients (17%), was not associated with the presence of hypertension (initial or subsequent).


CONCLUSIONS
In patients receiving tPA for stroke, absence of hypertension at presentation does not preclude subsequent increase in blood pressure. However, if blood pressure is not elevated during the first 6 hours, subsequent hypertension over the next 18 hours is unlikely. This study is small and retrospective, and needs to be repeated in a larger prospective cohort. However, our results provide preliminary evidence to suggest that where resources are scarce, these patients may be discharged from the intensive care unit earlier than the recommended 24 hours, provided that they are not at high risk for neurological deterioration.
Aiyagari
Venkatesh
V
Department of Neurology, Washington University School of Medicine, Campus Box 8111, 660 S. Euclid Avenue, St. Louis, MO 63110, USA. aiyagariv@neuro.wustl.edu
Gujjar
Arunodaya
A
Zazulia
Allyson R
AR
Diringer
Michael N
MN
D000368:Aged; D001794:Blood Pressure; D001795:Blood Pressure Determination; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D020521:Stroke / Q000188:drug therapy* / Q000503:physiopathology; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator